AntibodystaleBristol Myers SquibbPhase 2
nivolumab (Opdivo, Relatlimab FDC + Nivolumab)
Metastatic Triple-negative Breast Cancer · Metastatic Triple-negative Breast Cancer
#MetastaticTriple-negativeBreastC#Antibody#Phase2#항체#면역항체+2
효능 ORR 61.9%임상시험 1상태 RECRUITING